Retinoic acid analogues inhibit human herpesvirus 8 replication

Antiviral Therapy

Volumn 13, Issue 2, 2008, Pages 199-209

  Caselli, Elisabetta ^a   Galvan, Monica ^a   Santoni, Fabio ^a   Alvarez, Susana ^b   De Lera, Angel R ^b   Ivanova, Diana ^b,c   Gronemeyer, Hinrich ^c   Caruso, Arnaldo ^d   Guidoboni, Massimo ^e,f   Cassai, Enzo ^a   Dolcetti, Riccardo ^e   Di Luca, Dario ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF VIGO   (Spain)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d UNIVERSITY OF BRESCIA   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 7 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 3 PROPOXY 2 NAPHTHYL) 2,4,6 OCTATRIENOIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1,3 DIOXOLAN 2 YL]BENZOIC ACID; 4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; 7 (3,5 DI TERT BUTYLPHENYL) 3 METHYL 2,4,6 OCTATRIENOIC ACID; ALITRETINOIN; ANTIVIRUS AGENT; BEXAROTENE; BMS 453; BMS 493; CD 666; INTERFERON; LG 100567; LG 101506; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; UVI 2105; UVI 2107; UVI 2513; UVI 2521; UVI 3101;

ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IMMUNOFLUORESCENCE TEST; INTERFERON PRODUCTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; VIRUS TRANSCRIPTION;

ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HERPESVIRUS 8, HUMAN; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRETINOIN; VIRAL LOAD; VIRUS REPLICATION;

EID: 42149093355     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Cathomas G. Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. Herpes 2003; 10:72-77.
2. Regezi JA, MacPhail LA, Daniels TE, DeSouza YG, Greenspan JS, Greenspan D. Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells. Am J Pathol 1993; 143:240-249.
3. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993; 143:10-14.
4. Renwick N, Halaby T, Weverling GJ, et al. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 1998; 12:2481-2488.
5. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 1998; 394:588-592.
6. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11:381-395.
7. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11:1327-1332.
8. Senanayake S, Kelly J, Lloyd A, Waliuzzaman Z, Goldstein D, Rawlinson W. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol 2003; 71:399-403.
9. James JS. Kaposi's sarcoma: new topical treatment approved. AIDS Treat News 1999:1.
10. Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol 2000; 136:1461-1469.
11. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi' sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22:235-246.
12. Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol 2000; 1:307-314; discussion 315-306.
13. Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001; 2:77-87.
14. Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002; 16:421-429.
15. Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003; 139:178-186.
16. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunode-ficiency syndrome-associated Kaposi's sarcoma. Cancer 2002; 95:2555-2561.
17. Corbeil J, Rapaport E, Richman DD, Looney DJ. Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells. J Clin Invest 1994; 93:1981-1986.
18. Nagpal S, Cai J, Zheng T, et al. Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol 1997; 17:4159-4168.
19. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W. Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett 1995; 89:117-124.
20. Lingen MW, Polverini PJ, Bouck NP. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 1996; 74:476-483.
21. Ferrari N, Morini M, Pfeffer U, Minghelli S, Noonan DM, Albini A. Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res 2003; 9:6020-6029.
22. Dolcetti R, Di Luca, D, de Lera A. Natural and synthetic retinoids: structural bases and biological effects of potential clinical relevance for the prevention and treatment of infection-driven tumors. Anti-Infective Agents in Medicinal Chemistry 2006; 5:85-103.
23. Dominguez B, Pazos Y, de Lera AR. Stereocontrolled synthesis of 6-s-cis- and 6-s-trans-locked 9Z-retinoids by hydroxyl-accelerated Stille coupling of (Z)-tri-n-butylstannylbut-2-en-1-ol and bicyclic dienyl triflates. J Org Chem 2000; 65:5917-5925.
24. Pazos Y, de Lera AR. Stereoselective synthesis of 9-cis- retinoic acid based on stepwise or convergent suzuki coupling reactions. Tetrahedron Letters 1999; 40:8287-8290.
25. Caselli E, Galvan M, Cassai E, Caruso A, Sighinolfi L, Di Luca D. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood 2005; 106:2790-2797.
26. Caruso A, Rotola A, Comar M, et al. HHV-6 infects human aortic and heart microvascular endothelial cells, increasing their ability to secrete proinflammatory chemokines. J Med Virol 2002; 67:528-533.
27. Caselli EFS, Amici C, Di Luca D, Caruso A, Santoro MG. Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NFκB pathway. Blood 2007; 109:2718-2726.
28. Caselli E, Bracci A, Galvan M, et al. Human herpesvirus 6 (HHV-6) U94/REP protein inhibits betaherpesvirus replication. Virology 2006; 346:402-414.
29. Santoni F, Lindner I, Caselli E, Goltz M, Di Luca D, Ehlers B. Molecular interactions between porcine and human gammaherpesviruses: implications for xenografts? Xenotransplantation 2006; 13:308-317.
30. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997; 41:2754-2756.
31. Zhu W, Burnette A, Dorjsuren D, et al. Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother 2005; 49:4965-4973.
32. Sergerie Y, Boivin G. Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR. J Clin Microbiol 2003; 41:3897-3900.
33. Pelicano L, Li F, Schindler C, Chelbi-Alix MK. Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene 1997; 15:2349-2359.
34. Bourgeade MF, Besancon F. Induction of 2′,5′-oligoadenylate synthetase by retinoic acid in two transformed human cell lines. Cancer Res 1984; 44:5355-5360.
35. Faluhelyi Z, Rodler I, Csejtey A, Tyring SK, Ember IA, Arany I. All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner. Anticancer Res 2004; 24:807-809.
36. Hanley TM, Kiefer HL, Schnitzler AC, Marcello JE, Viglianti GA. Retinoid-dependent restriction of human immunodeficiency virus type 1 replication in monocytes/macrophages. J Virol 2004; 78:2819-2830.
37. Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia 2002; 16:463-472.
38. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol 2005; 17:447-455.
39. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346:799-802.
40. Cannon MJ, Dollard SC, Black JB, et al. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17:215-222.
41. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996; 10:1101-1105.
42. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801.
43. Lala DS, Mukherjee R, Schulman IG, et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 1996; 383:450-453.
44. Agarwal C, Chandraratna RA, Johnson AT, Rorke EA, Eckert RL. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J Biol Chem 1996; 271:12209-12212.
45. Szondy Z, Reichert U, Bernardon JM, et al. Induction of apoptosis by retinoids and retinoic acid receptor gamma-selective compounds in mouse thymocytes through a novel apoptosis pathway. Mol Pharmacol 1997; 51:972-982.
46. Zhang L, Nadzan AM, Heyman RA, et al. Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. J Med Chem 1996; 39:2659-2663.
47. Germain P, Kammerer S, Perez E, et al. Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep 2004; 5:877-882.
48. Ivanova D, Gaudon C, Rossin A, Bourguet W, Gronemeyer H. RAR-RXR selectivity and biological activity of new retinoic acid analogues with heterocyclic or polycyclic aromatic systems. Bioorg Med Chem 2002; 10:2099-2102.
49. Alvarez R, Vega MJ, Kammerer S, et al. 9-cis-Retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists. Bioorg Med Chem Lett 2004; 14:6117-6122.
50. Canan Koch SS, Dardashti LJ, Hebert JJ, et al. Identification of the first retinoid X, receptor homodimer antagonist. J Med Chem 1996; 39:3229-3234.
51. Schulman IG, Crombie D, Bissonette RP, et al. RXR-Specific Agonists and modulators: a new retinoid pharmacology. In Retinoids: the Biochemical and Molecular Basis of Vitamin A and retinoid action. Edited by Nau H, Blaner WS; Springer-Verlag, Berlin, Germany.
52. Canan Koch SS, Dardashti LJ, Cesario RM, et al. Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells. J Med Chem 1999; 42:742-750.
53. Dawson MI, Zhang XK. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr Med Chem 2002; 9:623-637.
54. Michellys PY, D'Arrigo J, Grese TA, et al. Design, synthesis and structure-activity relationship of novel RXR-selective modulators. Bioorg Med Chem Lett 2004; 14:1593-1598.